Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast
HOUSTON, May 8, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will report its financial results for the quarter ended March 31, 2024, on Friday, May 10, 2024. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13, 2024.
休斯頓，2024 年 5 月 8 日 — Moleculin Biotech有限公司，（納斯達克股票代碼：MBRX）（“Moleculin” 或 “公司”）是一家臨床階段製藥公司，擁有廣泛的針對難以治療的腫瘤和病毒的候選藥物組合。該公司今天宣佈，將於2024年5月10日星期五公佈截至2024年3月31日的季度財務業績。分子蛋白管理層將主持電話會議和 網絡直播音頻 將於美國東部時間2024年5月13日星期一上午8點30分討論運營和財務業績。
Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.
感興趣的參與者和投資者可以通過撥打（877）407-0832（國內）或（201）689-8433（國際）並參考Moleculin Biotech電話會議來參加電話會議。這個 網絡直播音頻 將在上面訪問 活動 的頁面 投資者 Moleculin網站的欄目， moleculin.com，並將存檔 90 天。
About Moleculin Biotech, Inc.
關於 Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above is subject to change.
Moleculin Biotech, Inc. 是一家臨床階段的製藥公司，針對難以治療的腫瘤和病毒的產品線不斷擴大，包括二期臨床項目。該公司的主要項目安那黴素是下一代蒽環素，旨在避免多藥耐藥機制，幾乎沒有心臟毒性。安那黴素目前正在開發中，用於治療復發或難治性急性髓系白血病（AML）和軟組織肉瘤（STS）肺轉移。上面討論的所有中期和初步數據可能會發生變化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.
此外，該公司正在開發免疫/轉錄調節劑 WP1066，一種免疫/轉錄調節劑，能夠抑制p-stat3和其他致癌轉錄因子，同時刺激針對腦腫瘤、胰腺和其他癌症的自然免疫反應，以及用於局部治療皮膚 T 細胞淋巴瘤的 WP1066 類似物 WP1220。Moleculin 還參與開發抗代謝藥物產品組合，包括用於潛在病毒治療的 WP1122，以及包括腦腫瘤、胰腺癌和其他癌症在內的癌症適應症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
如需了解有關公司的更多信息，請訪問 www.moleculin.com 然後連接 推特， 領英 和 Facebook。
Investor Contact:
投資者聯繫人：
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
JTC Team, LLC
珍妮·托馬斯
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-report-first-quarter-2024-financial-results-on-may-10-2024-and-host-conference-call-and-webcast-302138835.html
SOURCE Moleculin Biotech, Inc.
來源 Moleculin Biotech, Inc.
譯文內容由第三人軟體翻譯。